Repare Therapeutics INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Blue Owl Capital Holdings LP has filed an amendment to its Schedule 13G, reporting zero beneficial ownership of Repare Therapeutics Inc. common shares as of March 31, 2026.
SCHEDULE 13G: Shay Capital Discloses 6.7% Stake in Repare Therapeutics
Shay Capital LLC and Shay Capital Holdings LLC have reported a passive beneficial ownership of 6.7% in Repare Therapeutics Inc., totaling 2,870,141 common shares.
ARK Investment Management LLC has disclosed a 4.70% passive ownership stake in Repare Therapeutics Inc. as of December 31, 2024, according to a recent Schedule 13G filing.